Regeneron Pharmaceuticals, Inc. (REGN)

815,53 -8,28 (-1,01%) Ab 01:06PM EST. Markt geöffnet.

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 12.463

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Leonard S. Schleifer M.D., Ph.D.	Co-Founder, President, CEO & Co-Chairman	7M	N/A	1953
Dr. George D. Yancopoulos M.D., Ph.D.	Co-Founder, President, Chief Scientific Officer & Co-Chairman	6,59M	N/A	1960
Mr. Robert E. Landry Jr.	Executive VP of Finance & CFO	1,84M	11,1M	1964
Dr. Andrew J. Murphy Ph.D.	Executive Vice President of Research	1,62M	19,39M	1959
Mr. Daniel P. Van Plew	Executive VP and GM of Industrial Operations & Product Supply	1,95M	45,28M	1973
Ms. Marion E. McCourt	Executive Vice President of Commercial	1,5M	4,25M	1960
Ms. Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	N/A	N/A	N/A
Mr. Christopher R. Fenimore CPA	Senior VP, Head of Accounting & Controller	N/A	N/A	1971
Mr. Gerald Underwood	Senior Vice President of Technical Operations	N/A	N/A	N/A
Mr. Bob McCowan	Senior VP of IT & Chief Information Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Corporate Governance

Regeneron Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 28. November 2023, lautet 10. Die grundlegenden Scores sind Audit: 10, Vorstand: 9, Shareholderrechte: 10, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.